CJC-1295 / Ipamorelin Chicago — Chicagoland Peptides
CJC-1295 (a GHRH-pathway analog) and Ipamorelin (a selective secretagogue) are co-listed because pituitary pulse experiments often run them together. Laboratory notes emphasise timed hormone-axis sampling rather than replacement paradigms for Chicago and Chicagoland research buyers.
Lab report
Research guides
- CJC-1295 and Ipamorelin in Animal Growth Hormone Research: What the Published Literature ReportsA research-framing overview of how CJC-1295 and ipamorelin appear in the peer-reviewed musculoskeletal literature, drawing on a PRISMA-guided scoping review that found the evidence base is dominated by preclinical animal models, with human investigations limited and methodologically heterogeneous.
- CJC-1295 and Ipamorelin in the GH–IGF-1 Axis Literature: What Published Reviews ReportA research-framing overview of how two 2026 narrative reviews characterise CJC-1295 (with and without DAC) and ipamorelin within the growth hormone–IGF-1 axis literature, including how the reviews classify the strength of human evidence, reported adverse-effect domains, product-quality uncertainty, and antidoping context.
- Ipamorelin and the Ghrelin/GHSR System: What the Published Literature CoversA research-library summary of the available cited literature linking ipamorelin to the ghrelin/growth hormone secretagogue receptor (GHSR) axis, drawn from a teleost study in black seabream that characterised the ghrelin gene and examined ghrelin transcript levels after in vivo ipamorelin administration.
Chicagoland Peptides products are Research Use Only ("RUO") and are intended solely for basic research, pharmaceutical research, laboratory experimentation, or the development of new tests — not for diagnosing, treating, curing, or preventing any disease or condition in any patient. These statements have not been evaluated by the U.S. Food and Drug Administration.